GE Healthcare has completed the acquisition of Puridify, a bioprocessing start-up that is developing a nanofiber-based platform purification technology for biopharmaceutical production.

GE will acquire Puridify with its all 17 employees, who will join GE Healthcare Life Sciences’ BioProcess business.

The Puridify team will remain at their current location in Stevenage, UK, which will serve as a small research hub for BioProcess.

FibroSelect is the technology of Puridify which harmonizing to the bead resins and chromatography membranes.

This technology is used in downstream bioprocessing, promising faster mass transfer, scalability and ease of use.

“The technology that Puridify has been developing gives GE, access to exciting technology that could give considerable improvements for some customers in their purification step. The early feedback from collaborators has been positive. Today’s investment in this new technology is further evidence of GE’s strong commitment to innovation in the production of biopharmaceuticals to the benefit of our customers and of patients world-wide,” said Jan Makela, General Manager, BioProcess -GE Healthcare Life Sciences.

“Puridify has spent the last three years developing the industrial FibroSelect technology in close collaboration with leading biomanufacturers with promising results.We are excited to take this next step as part of GE Healthcare, with the full support and experience associated with one of the industry leaders in this field. Our goal is to introduce significant improvements to bioprocessing and being part of GE helps us to maximize this opportunity. This deal gives full recognition to Puridify’s development team and to the strong potential of the FibroSelect technology platform,” said Oliver Hardick, Chief Executive Officer, Puridify.